About CanAssist Breast

OncoStem Diagnostics has developed a novel, proteomics-based cancer recurrence risk predictor called CanAssist Breast, which integrates a patented biomarker analysis with clinicopathological parameters to arrive at the probability of distant recurrence within five years from diagnosis. It is a first-of-its-kind prognostic test developed using machine learning techniques that allows the assessment of non-linear interactions between biomarkers, which is critical given the crosstalk between different signaling pathways in cancer.

CanAssist Breast examines the expression of a unique combination of protein biomarkers from the patient’s tumor sample using the IHC platform at OncoStem’s central CAP-accredited laboratory. This information is combined with three clinicopathological parameters (tumor size, grade, and lymph node involvement) for a comprehensive risk assessment, and the risk of five-year distant recurrence is calculated with the help of our proprietary AI-powered algorithm.

Risk Stratification Score
The CanAssist Breast algorithm produces a risk score ranging from 0-100. A cut-off of 15.5 is applied to stratify patients into either low-risk (score ≤15.5) or high-risk (score >15.5) categories of distant cancer recurrence.

• Low-risk: Less likely to benefit from chemotherapy.
• High-risk: need chemotherapy and additional therapies as applicable for better outcomes.

Combined with other clinical data, CanAssist Breast provides prognostic information with detailed personalized cancer recurrence risk insights, empowering doctors to make data-driven, precise treatment decisions for early-stage breast cancer patients.